Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry
Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-05-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/HS9.0000000000000711 |
| _version_ | 1827333308953919488 |
|---|---|
| author | Marie-Kristin Tilch Carlo Visco Sandra Kinda Olivier Hermine Milena Kohn Caroline Besson Sylvain Lamure Rémy Duléry Simone Ragaini Toby A. Eyre Tom Van Meerten Anke Ohler Steffen Eckerle Martin Dreyling Georg Hess Eva Giné Maria Gomes da Silva |
| author_facet | Marie-Kristin Tilch Carlo Visco Sandra Kinda Olivier Hermine Milena Kohn Caroline Besson Sylvain Lamure Rémy Duléry Simone Ragaini Toby A. Eyre Tom Van Meerten Anke Ohler Steffen Eckerle Martin Dreyling Georg Hess Eva Giné Maria Gomes da Silva |
| author_sort | Marie-Kristin Tilch |
| collection | DOAJ |
| description | Data on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44–84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (P = 0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort. |
| first_indexed | 2024-03-07T17:19:19Z |
| format | Article |
| id | doaj.art-a95d5933e93242e49840125b0b689971 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:19:19Z |
| publishDate | 2022-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-a95d5933e93242e49840125b0b6899712024-03-02T21:01:20ZengWileyHemaSphere2572-92412022-05-0165e071110.1097/HS9.0000000000000711202205000-00001Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL RegistryMarie-Kristin Tilch0Carlo Visco1Sandra Kinda2Olivier Hermine3Milena Kohn4Caroline Besson5Sylvain Lamure6Rémy Duléry7Simone Ragaini8Toby A. Eyre9Tom Van Meerten10Anke Ohler11Steffen Eckerle12Martin Dreyling13Georg Hess14Eva Giné15Maria Gomes da Silva161 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany2 Department of Medicine, Section of Hematology, University of Verona, Verona, Italy3 University Hospital Center Zagreb, Department of Internal Medicine, Division of Hematology, Zagreb, Croatia4 Department of Hematology, Hôpital Necker, Assistance Publique—Hôpitaux de Paris, France5 Service d’Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Montigny le Bretonneux, France5 Service d’Hématologie Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France; Université Versailles Saint Quentin en Yvelines, Université Paris-Saclay, Montigny le Bretonneux, France6 Departement d’Hématologie Clinique, CHU de Montpellier, UMR-CNRS 5535, Université de Montpellier, France7 Sorbonne Université, INSERM UMRs938, Service d’Hématologie Clinique et de Thérapie Cellulaire, Hôpital Saint Antoine, AP-HP, Paris, France8 Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino/“Città della Salute e della Scienza di Torino” University Hospital, Turin, Italy9 Department of Clinical Hematology, Oxford Cancer and Hematology Centre, Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford, United Kingdom10 Department of Hematology, University of Groningen, University Medical Center Groningen, Netherlands1 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany1 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany11 Department of Medicine III, LMU Hospital, Munich, Germany1 Department of Hematology, Oncology and Pneumology & University Cancer Center, University Medical Center of the Johannes Gutenberg-University, Mainz, Germany12 Department of Hematology, Hospital Clinic of Barcelona, IDIBAPS, Barcelona, Spain13 Department of Hematology, Instituto Português de Oncologia de Lisboa, PortugalData on outcome of patients with mantle cell lymphoma (MCL) and COVID-19 infection are limited. The European MCL (EMCL) registry is a centralized registry of the EMCL network, collecting real-world information about treatments and disease courses. During the COVID-19 pandemic, additional data on MCL patients with COVID-19 infection were collected, aiming to identify risk factors for mortality from COVID-19. In our retrospective, multicenter, international study, we collected data from 63 MCL patients with a median age of 64 years (range, 44–84) in 9 countries with evidence of a COVID-19 infection between February 2020 and October 2021. The overall mortality rate was high (44.4%), especially in hospitalized patients (61%) and in patients with need for intensive care unit care (94%). Patients receiving rituximab had significantly poorer survival than patients not receiving rituximab (P = 0.04). Our data highlight the importance of prevention strategies and underline the need for effective vaccination in this vulnerable cohort.http://journals.lww.com/10.1097/HS9.0000000000000711 |
| spellingShingle | Marie-Kristin Tilch Carlo Visco Sandra Kinda Olivier Hermine Milena Kohn Caroline Besson Sylvain Lamure Rémy Duléry Simone Ragaini Toby A. Eyre Tom Van Meerten Anke Ohler Steffen Eckerle Martin Dreyling Georg Hess Eva Giné Maria Gomes da Silva Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry HemaSphere |
| title | Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry |
| title_full | Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry |
| title_fullStr | Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry |
| title_full_unstemmed | Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry |
| title_short | Outcome of COVID-19 in Patients With Mantle Cell Lymphoma—Report From the European MCL Registry |
| title_sort | outcome of covid 19 in patients with mantle cell lymphoma report from the european mcl registry |
| url | http://journals.lww.com/10.1097/HS9.0000000000000711 |
| work_keys_str_mv | AT mariekristintilch outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT carlovisco outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT sandrakinda outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT olivierhermine outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT milenakohn outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT carolinebesson outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT sylvainlamure outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT remydulery outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT simoneragaini outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT tobyaeyre outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT tomvanmeerten outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT ankeohler outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT steffeneckerle outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT martindreyling outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT georghess outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT evagine outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry AT mariagomesdasilva outcomeofcovid19inpatientswithmantlecelllymphomareportfromtheeuropeanmclregistry |